Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Recruiting 3Not yet recruiting 3

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 43Thoracic 26Head & Neck 17Dermatologic 7Breast 7Other solid neoplasm 6Genitourinary 6Tumor-Agnostic 4Lymphoid 4Gynecologic 3CNS 3Sarcoma 2Other hematologic neoplasm 1

Conditions

Advanced Solid Tumors 2Solid Tumors 1Solid Tumor 1Advanced Refractory Solid Tumors 1Advanced Malignant Solid Tumors 1

Interventions

pembrolizumab 77Injections 67Carboplatin 38Nivolumab 31Pemetrexed 29Cisplatin 29Cyclophosphamide 25Specimen Handling 24Interviews as Topic 24tislelizumab 20atezolizumab 20Bevacizumab 20Paclitaxel 19fludarabine 16Standard of Care 16Practice Guidelines as Topic 16Docetaxel 16Ipilimumab 15toripalimab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Immune Checkpoint Inhibitors × Other solid neoplasm × 1 year × Clear all
NCT06819735 2026-05-06

DOMISOL

Domain Therapeutics SA

Phase 1/2 Recruiting
125 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT06349837 2026-05-01

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Sichuan University

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Tongji Hospital

Phase 2 Not yet recruiting
60 enrolled
Other solid neoplasm

Solid Tumors

NCT07363369 2026-01-23

Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

West China Hospital

Phase 1 Not yet recruiting
10 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
40 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

NCT07285395 2025-12-16

AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study

The Affiliated Hospital of Xuzhou Medical University

Phase 1 Recruiting
12 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡